6. Cardiomyopathie en hartfalen.....................................................................................................................................3
Hartfalen......................................................................................................................................................................3
A. Etiologie...............................................................................................................................................................3
Epidemiology of Heart Failure (U.S).....................................................................................................................3
Cardiomyopathie.........................................................................................................................................................3
A. Cardiomyopathie: indeling..................................................................................................................................4
B. Gedilateerde CMP...............................................................................................................................................4
C. Hypertrofe CMP...................................................................................................................................................4
Hypertrofe obstructieve CMP: asymmetrische hypertrofie.................................................................................4
Hypertrofe CMP: kliniek......................................................................................................................................5
Sporthart.............................................................................................................................................................5
Echocardiografische kenmerken van Athlete’s Heart..........................................................................................5
1. LV remodeling na trainingsstop...................................................................................................................5
D. Restrictieve CMP: zeldzaam................................................................................................................................5
Symptomen hartfalen..................................................................................................................................................6
A. Symptomen : pathofysiologie..............................................................................................................................6
B. Linker hartfalen...................................................................................................................................................7
C. Rechter Hartfalen................................................................................................................................................7
Symptomen.........................................................................................................................................................7
1. Cardiale cachexie: >6% gewichtsverlies.......................................................................................................7
NYHA* classificatie ernst hartfalen..............................................................................................................................8
Ventrikeldysfunctie limiteert de patient in zijn dagdagelijkse activiteiten..........................................................8
Levenskwaliteit....................................................................................................................................................8
A. Cardiogene shock: zeer ernstig hartfalen............................................................................................................8
B. Swan Ganz catheters...........................................................................................................................................8
Thermodilutie......................................................................................................................................................9
C. Cardiogenic shock................................................................................................................................................9
Renine angiotensine aldosterone system............................................................................................................9
Diagnostische evaluatie hartfalen...............................................................................................................................9
A. Therapie Hartfalen: Doelstellingen....................................................................................................................10
B. Therapie Hartfalen: algemene maatregelen......................................................................................................10
Aangrijpingspunten hartfalen medicatie...........................................................................................................10
Medicamenteuze therapie........................................................................................................................................10
Specifieke behandeling..............................................................................................................................................10
A. AICD.................................................................................................................................................................. 10
B. Cardiale resynchronisatie therapie (CRT)..........................................................................................................11
CRT bij linker bundeltakblok..............................................................................................................................11
Pre breed QRS....................................................................................................................................................11
, Post smal QRS....................................................................................................................................................11
C. Harttransplantatie.............................................................................................................................................12
D. Assist devices (kunsthart)..................................................................................................................................12
One-Year Mortality After Admission for First Hospitalization for Heart Failure in 1988-2000...........................12
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller charlottedevooght. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $3.23. You're not tied to anything after your purchase.